The earnings call reflects a generally positive outlook with significant advances in clinical programs, especially with the CD47 biomarker-driven strategy that shows promise for targeted oncology approaches. The extension of the cash runway and progress in partnered studies further strengthen the company's position. However, challenges remain in defining specific biomarker cutoffs and addressing unmet needs in HER2-positive breast cancer. Overall, the call suggests optimism for future developments.

Company Guidance

During the Q2 2025 earnings call, the company provided several key updates and metrics regarding its ongoing clinical programs and financial outlook. The ASPEN-06 trial showed that CD47 expression is a predictive biomarker, significantly enhancing the clinical response to evorpacept in patients with high CD47 expression, with an observed overall response rate (ORR) of 65% compared to 26% in the control group. This finding has led to a modification in the Phase II breast cancer trial to a CD47 and HER2 biomarker-driven strategy. Financially, the company extended its cash runway guidance into Q1 2027, which is expected to support multiple upcoming data milestones. The company also announced that its novel EGFR-targeted antibody-drug conjugate, ALX2004, is set to enter clinical trials. Additionally, the completion of the Phase I/II UMBRELLA study with partner Sanofi was highlighted, with plans to move forward with dose optimization. These strategic updates are part of a focused development strategy aimed at leveraging the predictive power of CD47 to enhance therapeutic outcomes in oncology.

Significant Advances in Clinical Programs

The company made significant advances in both the evorpacept and ALX2004 clinical programs, including new data from the ASPEN-06 trial showing CD47 expression as a key predictive biomarker for clinical response with evorpacept.

CD47 Biomarker-Driven Strategy

Analysis indicates patients with high CD47 expression benefit significantly more from evorpacept, leading to a modified Phase II clinical trial in breast cancer with a CD47 and HER2 biomarker-driven strategy.

Financial Guidance and Cash Runway Extension

The company has extended its cash runway guidance into Q1 2027, solidly positioning it to achieve multiple value-enhancing data milestones in the coming years.

Progress with Partnered Studies

The UMBRELLA study with Sanofi evaluating evorpacept with SARCLISA and dexamethasone in multiple myeloma is now complete, moving to dose optimization.

ALX Oncology Holdings (ALXO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALXO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.33 / -	-0.58	―	―	―
Aug 12, 2025	2025 (Q2)	-0.42 / -0.49	-0.76	35.53% (+0.27)
May 08, 2025	2025 (Q1)	-0.46 / -0.58	-0.71	18.31% (+0.13)	―	―
Mar 06, 2025	2024 (Q4)	-0.67 / -0.55	-0.93	40.86% (+0.38)	―	―
Nov 07, 2024	2024 (Q3)	-0.78 / -0.58	-1.24	53.23% (+0.66)	―	―
Aug 08, 2024	2024 (Q2)	-0.75 / -0.76	-0.84	9.52% (+0.08)	―	―
May 09, 2024	2024 (Q1)	-0.82 / -0.71	-0.74	4.05% (+0.03)	―	―
Mar 07, 2024	2023 (Q4)	-0.88 / -0.93	-0.75	-24.00% (-0.18)	―	―
Nov 13, 2023	2023 (Q3)	-0.85 / -1.24	-0.87	-42.53% (-0.37)	―	―
Aug 09, 2023	2023 (Q2)	-0.88 / -0.84	-0.81	-3.70% (-0.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALXO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$0.62	$0.66	+6.45%
May 08, 2025	$0.48	$0.46	-4.17%
Mar 06, 2025	$1.31	$1.06	-19.08%
Nov 07, 2024	$1.51	$1.45	-3.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alx Oncology Holdings, Inc. (ALXO) report earnings?

Alx Oncology Holdings, Inc. (ALXO) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Alx Oncology Holdings, Inc. (ALXO) earnings time?

Alx Oncology Holdings, Inc. (ALXO) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALXO EPS forecast?

ALXO EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing